Picture of Abbvie logo

ABBV Abbvie News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

REG-AbbVie Inc.: Rule 2.10 Announcement

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE
OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

NORTH CHICAGO, Ill., April 15, 2020 -- In accordance with Rule 2.10 of the
Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that
as of April 13, 2020 its issued share capital, excluding treasury shares, is
comprised of 1,476,730,009 shares of common stock with a par value of $0.01
per share. AbbVie's common stock is traded on the NYSE and Chicago Stock
Exchange under the symbol ABBV.  The International Securities Identification
Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on April 13, 2020, there
were outstanding 8,298,905 options to purchase shares of common stock (the
"Stock Options"), 7,925,412 restricted stock units (the "Restricted Stock
Units") and 2,680,140 performance shares (the "Performance Shares"). Upon
exercise, each Stock Option entitles the holder to purchase one share of
common stock at the applicable exercise price. Upon vesting, each Restricted
Stock Unit and Performance Share entitles the holder to receive one share of
common stock.

The Directors of AbbVie Inc. accept responsibility for the information
contained in this announcement. To the best of their knowledge and belief
(having taken all reasonable care to ensure such is the case), the information
contained in this announcement is in accordance with the facts and does not
omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc.
may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel
Act, 1997, Takeover Rules 2013.

SOURCE AbbVie

CONTACT: Adelle Infante, 1-847-938-8745



Copyright (c) 2020 PR Newswire Association,LLC. All Rights Reserved

Recent news on Abbvie

See all news